Autonomix medical, inc. technology and early proof-of-concept study results to be featured in poster presentation at the world-leading course in interventional cardiovascular medicine, europcr

The woodlands, tx, april 24, 2025 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced its technology and early proof-of-concept study results will be featured in a poster presentation as part of pcr innovators day at the world-leading course in interventional cardiovascular medicine, europcr, being held may 20-23, 2025 in paris, france.
AMIX Ratings Summary
AMIX Quant Ranking